Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

Abstract In the BrighTNess trial, carboplatin added to neoadjuvant chemotherapy (NAC) was associated with increased pathologic complete response (pCR) rates in patients with stage II/III triple-negative breast cancer (TNBC). In this matched cohort study, cases with a germline BRCA1/2 mutation (gBRCA...

Full description

Saved in:

Bibliographic Details
Main Authors:	Otto Metzger-Filho, Katharine Collier, Sarah Asad, Peter J. Ansell, Mark Watson, Junu Bae, Mathew Cherian, Joyce O’Shaughnessy, Michael Untch, Hope S. Rugo, Jens B. Huober, Mehra Golshan, William M. Sikov, Gunter von Minckwitz, Priya Rastogi, Lang Li, Lijun Cheng, David Maag, Norman Wolmark, Carsten Denkert, W. Fraser Symmans, Charles E. Geyer, Sibylle Loibl, Daniel G. Stover
Format:	article
Language:	EN
Published:	Nature Portfolio 2021
Subjects:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Online Access:	https://doaj.org/article/c6af5c9ea1394c7ab85bf5141ac651b6
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

Similar Items